Biopharma

No results found for this search.

• • Biopharma
  • Biotech + Life Sciences
  • Online

  Registration for MALSI+ 2021 is open

  Don’t miss the Commonwealth’s flagship event connecting scientific innovators, entrepreneurs, business leaders, and investors to celebrate the many ways Massachusetts leads the nation in bringing translational science to the market!...

• • Biopharma

  Biogen to make experimental ALS drug available to dying patients

• • Biopharma
  • COVID-19

  The new mRNA vaccines from Pfizer and Moderna to fight the coronavirus are based on a technology that could transform the future of medicine.

• • Biopharma

  Biological sensors developed by Glympse Bio, a startup that spun out of the lab of MIT Professor Sangeeta Bhatia, could help clinicians make decisions for individual patients.

• 

  • Biopharma
  • Biotech + Life Sciences
  • Online

  The ‘Invisible’ Future of Health Monitoring

  If the current pandemic has taught us anything, it is the importance of monitoring not only our own health but the health of our loved ones. It has reiterated the...

• • Biopharma
  • Biotech + Life Sciences
  • Learning
  • Online

  Business of Biotech 201: From Molecule to Market, R&D and Regulatory Considerations

  Discounts for MassBio Member Companies: MassBio Members receive discounts on all of our courses. Check here to see if your company is a MassBio Member. If so, please contact courses@massbioed.org...

• • Biopharma
  • Biotech + Life Sciences
  • Learning
  • Online

  Business of Biotech 201: From Molecule to Market, R&D and Regulatory Considerations

  Discounts for MassBio Member Companies: MassBio Members receive discounts on all of our courses. Check here to see if your company is a MassBio Member. If so, please contact courses@massbioed.org...

• • Biopharma
  • Biotech + Life Sciences
  • Learning
  • Online

  Business of Biotech 201: From Molecule to Market, R&D and Regulatory Considerations

  Discounts for MassBio Member Companies: MassBio Members receive discounts on all of our courses. Check here to see if your company is a MassBio Member. If so, please contact courses@massbioed.org...

• 

  • Biopharma
  • Biotech + Life Sciences
  • KSA Programming

  Future of (how we) Work Task Force

  Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...

• 

  • Biopharma
  • Biotech + Life Sciences
  • KSA Programming

  Future of (how we) Work Task Force

  Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...

• 

  • Biopharma
  • Biotech + Life Sciences
  • KSA Programming

  Future of (how we) Work Task Force

  Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...

• 

  • Biopharma
  • Biotech + Life Sciences
  • KSA Programming

  Future of (how we) Work Task Force

  Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...

• 

  • Biopharma
  • Biotech + Life Sciences
  • KSA Programming

  Future of (how we) Work Task Force

  Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...

• 

  • Biopharma
  • Biotech + Life Sciences
  • KSA Programming

  Future of (how we) Work Task Force

  Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...

• 

  • Biopharma
  • Biotech + Life Sciences
  • KSA Programming

  Future of (how we) Work Task Force

  Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...

• 

  • Biopharma
  • Biotech + Life Sciences
  • KSA Programming

  Future of (how we) Work Task Force

  Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...

• 

  • Biopharma
  • Biotech + Life Sciences
  • KSA Programming

  Future of (how we) Work Task Force

  Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...

• 

  • Biopharma
  • Biotech + Life Sciences
  • KSA Programming

  Future of (how we) Work Task Force

  Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...

• 

  • Biopharma
  • Biotech + Life Sciences
  • KSA Programming

  Future of (how we) Work Task Force

  Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...

• 

  • Biopharma
  • Biotech + Life Sciences
  • KSA Programming

  Future of (how we) Work Task Force

  Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...

• 

  • Biopharma
  • Biotech + Life Sciences
  • KSA Programming

  Future of (how we) Work Task Force

  Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...

• • Biopharma

  Biogen, placing a major bet on a once-failed treatment, is paying $1.53 billion for the commercial rights to a Sage Therapeutics’ oral depression drug, zuranolone.

• • Biopharma
  • Biotech + Life Sciences

  Last week, Anne Heatherington, Ph.D., senior vice president and head of Data Sciences Institute at Takeda shared that competitive barriers that typically limit the sharing of data have been broken down during the global response.

• • Biopharma

  Johnson & Johnson entered its final stage of clinical trials for its COVID-19 vaccine. What differentiates their vaccine candidate from others is that it does not need to be frozen and may require just one injection.

• • Biopharma
  • Biotech + Life Sciences

  Nine CEOs signed a pledge outlining a united commitment to sustain the integrity of the scientific process as they work toward potential regulatory filings and approvals of the first COVID-19 vaccines.

• • Biopharma
  • Biotech + Life Sciences

  Bayer has entered a collaboration agreement with Recursion Pharmaceuticals to strengthen AI-guided drug discovery and advance new treatments for fibrotic diseases of the lung, kidney, heart, and more.

• 

  • Biopharma
  • Biotech + Life Sciences
  • Learning
  • Online

  Open Innovation Event Webinar

  10:00 – 10:15 AM | Opening by Andy Topping, CSO, FUJIFILM Diosynth Biotechnologies 10:15 – 10:45 AM | Real Time Metabolomics in Biotechnology and Biopharma | Karl Burgess, Senior Lecturer...

• • Biopharma

  Moderna CEO sees ‘high probability’ of success with Covid-19 vaccine

  Recent history suggests a new vaccine entering human clinical trials has about a 1-in-3 chance of getting FDA approval. Stephane Bancel, chief executive of Moderna, pegs the chances of his company’s novel coronavirus vaccine at closer to 80% to 90%.